ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium

NCT07414940 | Not Yet Recruiting Phase 1 DMC

• 1 other identifier: 158145
• Study Type: interventional
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

Advanced metastatic castration-resistant prostate cancer is a medical condition for which additional effective and tolerable treatments are urgently needed in order to improve patient outcomes and quality of life. The goal of this clinical trial is to learn more about Actinium (225Ac) radiohybrid prostate-specific membrane antigen-10.1 (rhPSMA-10.1) injection in men with prostate cancer that has spread and progressed after previous treatments, particularly after Lutetium-PSMA. Actinium (225Ac) rhPSMA-10.1 is an injectable radioactive medication that aims to attach to prostate cancer cells in the body and destroy them using ionising radiation. It is a new medication that has not yet been studied in humans. Participants will receive a dose of Actinium (225Ac) rhPSMA-10.1 every 6 weeks, to a maximum of 6 doses. They will be reviewed regularly by the trial researchers to monitor side effects and safety signals. A range of medication doses will be administered so that researchers can find out what doses of the medication are safe for men with prostate cancer. The trial will also aim to determine how effective this medication is for treating advanced prostate cancer.

Conditions

Metastatic Castration-resistant Prostate Cancer; Metastatic Prostate Cancer; Prostate Cancer

Keywords

PSMA; mCRPC; Prostate Cancer

Outcome Measures

Primary Outcomes (2)

• Phase I incidence of dose-limiting toxicities (DLTs)

  Incidence of DLTs during the DLT observation period

  From time of IMP administration until completion of the dose-limiting toxicity period, which is 6 weeks.

• Phase II anti-tumour response

  Proportion of patients with response to treatment, defined as either (or both) of: PSA reduction of ≥ 50% from baseline (PSA50), objective radiographic response as assessed by imaging using Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) with Prostate Cancer Working Group 3 (PCWG3) recommendations

  From date of IMP administration until the occurrence of PSA nadir (for PSA50) or best radiographic response (for Objective Radiographic Response), monitored for a maximum of 5 years.

Study Arms (2)

Phase I dose escalation/de-escalation of Actinium (225Ac) rhPSMA-10.1

EXPERIMENTAL

Participants with advanced metastatic castration-resistant prostate cancer (mCRPC) will receive Actinium (225Ac) rhPSMA-10.1. The dose received by successive participants will be determined according to a pre-specified dose escalation/de-escalation scheme.

Drug: Actinium (225Ac) rhPSMA-10.1

Phase II cohort expansion at recommended Phase II dose

EXPERIMENTAL

Participants with advanced metastatic castration-resistant prostate cancer (mCRPC) will receive Actinium (225Ac) rhPSMA-10.1 at the recommended Phase II dose determined in Phase I.

Drug: Actinium (225Ac) rhPSMA-10.1

Interventions

Actinium (225Ac) rhPSMA-10.1 DRUG

Dose will vary depending on trial phase and dose escalation/de-escalation stage

Phase I dose escalation/de-escalation of Actinium (225Ac) rhPSMA-10.1; Phase II cohort expansion at recommended Phase II dose

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years at time of providing informed consent.
• Histologically- or cytologically-confirmed diagnosis of prostate adenocarcinoma, which may include small cell or neuroendocrine features.
• Castration-resistant prostate cancer, defined as a rising PSA despite surgical castration or ongoing medical castration, with serum testosterone ≤ 0.5ng/mL or \<1.7 nmol/L.
• Progressive mCRPC with rising PSA level, as defined by PCWG3 criteria, or by radiological progression, and must demonstrate a sequence of rising values above baseline at a minimum of 1-week intervals and PSA \> 1 ng/mL.
• PSMA-avid disease on screening PSMA-PET-CT scan
• Prior treatment with at least one second-generation androgen receptor pathway inhibitor (ARPI)
• Prior treatment with at least one but no more than two lines of taxane therapy for prostate cancer, or been deemed ineligible or refused taxane therapy on consultation with their treating physician.
• At least 4 weeks or 5 half-lives (whichever is longer) elapsed between last anti-cancer treatment administration and the initiation of trial treatment. Anti-cancer treatment includes ARPIs and PARP inhibitors but excludes ADT (e.g. luteinising hormone releasing hormone (LHRH) analogue or gonadotropin-releasing hormone treatment), which should be continued. Prednisone up to 10 mg daily (or equivalent) is also permitted.
• Prior treatment with 177Lu-PSMA-targeted radiopharmaceutical therapy (e.g. 177Lu-PSMA-617, 177Lu PSMA-I\&T) up to a maximum of 6 cycles and with response to therapy as judged by the treating physician.
• Exception: in Phase I, the first 3 participants treated at each dose level may be 177Lu-PSMA naïve Note: last treatment with 177Lu-PSMA must be more than 10 weeks prior to study enrolment.
• Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.
• Estimated life expectancy \> 12 weeks.
• Grade ≤ 1 xerostomia symptoms at time of trial enrolment.
• Adequate bone marrow, renal, and hepatic function
• Resolution of all previous treatment-related toxicities to CTCAE v5.0 Grade ≤ 1, except for chemotherapy-induced alopecia, Grade 2 peripheral neuropathy, and Grade 2 urinary frequency, which are permitted.

You may not qualify if:

• Symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression.
• Active metastatic central nervous system (CNS) disease, including leptomeningeal disease.
• Receipt of 177Lu-PSMA treatment within 10 weeks of trial enrolment.
• Prior radiotherapeutic treatment for metastatic prostate cancer (e.g. Radium-223) with the exception of 177Lu-PSMA.
• Note: prior radiotherapeutic treatment for other cancers is permitted (e.g. radioactive iodine for thyroid cancer).
• Receipt of transfused blood products or erythropoietin stimulating agents within 4 weeks of trial enrolment.
• Major surgery within 12 weeks of trial enrolment.
• Other current malignancy, or malignancy diagnosed/relapsed within the past 5 years (other than non melanomatous skin cancer, stage 0 melanoma in situ, or non-muscle invasive bladder cancer that has undergone curative intent therapy).
• Sjogren's disease or any other medical conditions that in the judgement of the investigator puts the participant at increased risk of xerostomia.
• Single kidney, renal transplant or any nephrotoxic condition or concomitant therapy that in the judgement of the investigator could put the participant at risk of unacceptable renal toxicity during the trial.
• Severe urinary incontinence or any other conditions that in the judgement of the investigator would preclude safe disposal of radioactive urine.
• Any structural kidney/renal tract disease that in the judgement of the investigator could affect excretion of the trial agent (e.g. hydronephrosis), unless addressed with intervention (e.g. ureteric stent insertion with normalisation of renal function).
• Clinically significant abnormalities on a single 12-lead electrocardiogram (ECG) during screening evaluation.
• Concurrent serious conditions that in the judgement of the investigator would pose a safety risk or impair trial participation.
• Radiation therapy within 2 weeks before trial enrolment.

Sponsors & Collaborators

• University College, London: lead
• Blue Earth Therapeutics Ltd: collaborator

MeSH Terms

Conditions

Prostatic Neoplasms

Interventions

Actinium

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Actinoid Series Elements; Elements, Radioactive; Elements; Inorganic Chemicals; Metals, Heavy; Radioisotopes; Isotopes; Metals

Study Officials

• Gerhardt Attard

  University College, London

  STUDY DIRECTOR

Central Study Contacts

Trial Manager

CONTACT

02076799274; ncita.actinium@ucl.ac.uk

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Phase I: dose escalation/de-escalation, Phase II: cohort expansion at recommended Phase II dose

Study Record Dates

• First Submitted: August 22, 2024
• First Posted: February 17, 2026
• Study Start: March 1, 2026
• Primary Completion (Estimated): March 30, 2031
• Study Completion (Estimated): December 30, 2031
• Last Updated: February 17, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share